Orchard Secures New Libmeldy Price In Germany
Orchard Therapeutics says it is confident in the success of its gene therapy for MLD, which has secured the highest possible benefit rating from the German authorities.
You may also be interested in...
Europe: Cross-Country HTA of Gene Therapy Libmeldy Calls For Price Cut
Joint price negotiations for Orchard’s gene therapy Libmeldy could follow outcome of multi-country health technology assessment.
At Hard-Hit Gene Therapy Company Freeline, CEO Believes A Turnaround Is Possible
Michael Parini talks to Scrip about how a new focus at the company can help it prove the value of its AAV-based gene therapy platform.
Germany To Honor Pledge To Cut Spending On Medicines
Germany looks set to introduce new measures to curb pharmaceutical spending, including higher mandatory rebates for outpatient drugs and combination products. It will also lower the threshold at which orphan drugs must undergo a benefit assessment.